Acquisition strengthens Bayer’s drug discovery capabilities
News
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement
Libtayo plus platinum-doublet chemotherapy led to a 29% reduction in risk of death compared to chemotherapy alone
Sierra Oncology licenses myelofibrosis candidate from AstraZeneca
Planned Phase II study to combine the BET inhibitor with momelotinib
Pfizer, Flynn accused of charging the NHS ‘unfairly high prices’ for anti-epilepsy drug
UK Competition and Markets Authority provisionally finds drug companies broke competition law
Report finds reducing primary care antibiotic use ‘not enough’ to halt antimicrobial resistance
Drug resistant E. coli infections were not halted by reduction, according to new report
NICE pens two-year collaboration with the Academic Health Science Network
Agreement will support use of the ‘best evidence-based healthcare’ in the NHS
Positive Phase III results for Valneva’s chikungunya vaccine
Neutralising antibody titers were observed in 98.5% of subjects
16- and 17-year-olds should receive first COVID-19 vaccine, advises JCVI
Vaccine side effects rare and outweighed by the benefits
BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma
Phase III trials did not demonstrate sufficient clinical benefit.
Long COVID rare in children, KCL study finds
Less than one in 20 children had symptoms for more than four weeks
UK trial to assess Sativex for the treatment of ‘aggressive’ brain tumours
Sativex is a complex botanical formulation that contains the principal cannabinoids THC and CBD
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma
First treatment to be approved for UK MPM patients for more than 15 years
CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug
The £100m fine sends ‘a clear message’ to the pharma sector, said the CMA
Tecentriq wins FDA priority review for certain early NSCLC patients
Tecentriq is first and only cancer immunotherapy with positive Phase III results in adjuvant lung cancer setting
Gov’t launches study on COVID-19 vaccine dose interval for pregnant women
The study will be the largest clinical trial of its kind in the UK, involving over 600 pregnant women
